Cargando…
Potent and Persistent Antibody Response in COVID-19 Recovered Patients
SARS-CoV-2 has caused a global pandemic with millions infected and numerous fatalities. Virus-specific antibodies can be detected in infected patients approximately two weeks after symptom onset. In this study, we set up ELISA technology coating with purified SARS-CoV-2 S and N proteins to study the...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8193946/ https://www.ncbi.nlm.nih.gov/pubmed/34122416 http://dx.doi.org/10.3389/fimmu.2021.659041 |
_version_ | 1783706324734836736 |
---|---|
author | Tian, Xiaodong Liu, Ling Jiang, Wenguo Zhang, He Liu, Wenjun Li, Jing |
author_facet | Tian, Xiaodong Liu, Ling Jiang, Wenguo Zhang, He Liu, Wenjun Li, Jing |
author_sort | Tian, Xiaodong |
collection | PubMed |
description | SARS-CoV-2 has caused a global pandemic with millions infected and numerous fatalities. Virus-specific antibodies can be detected in infected patients approximately two weeks after symptom onset. In this study, we set up ELISA technology coating with purified SARS-CoV-2 S and N proteins to study the antibody response of 484 serum samples. We established a surrogate viral inhibition assay using SARS-CoV-2 S protein pseudovirus system to determine the neutralization potency of collected serum samples. Here, we report robust antibody responses to SARS-CoV-2 in 484 recovered patients varying from 154 to 193 days, with 92% of recovered patients displaying a positive virus-specific spike glycoprotein IgG (s-IgG) response, while the ratio of positive spike glycoprotein IgM (s-IgM) reached 63%. Furthermore, moderate to potent neutralization activities were also observed in 62% of patients, correlating significantly with s-IgG response. This study strongly supports the long-term presence of antibodies in recovered patients against SARS-CoV-2, although all serum samples were collected from individuals with mild or moderate symptoms. |
format | Online Article Text |
id | pubmed-8193946 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-81939462021-06-12 Potent and Persistent Antibody Response in COVID-19 Recovered Patients Tian, Xiaodong Liu, Ling Jiang, Wenguo Zhang, He Liu, Wenjun Li, Jing Front Immunol Immunology SARS-CoV-2 has caused a global pandemic with millions infected and numerous fatalities. Virus-specific antibodies can be detected in infected patients approximately two weeks after symptom onset. In this study, we set up ELISA technology coating with purified SARS-CoV-2 S and N proteins to study the antibody response of 484 serum samples. We established a surrogate viral inhibition assay using SARS-CoV-2 S protein pseudovirus system to determine the neutralization potency of collected serum samples. Here, we report robust antibody responses to SARS-CoV-2 in 484 recovered patients varying from 154 to 193 days, with 92% of recovered patients displaying a positive virus-specific spike glycoprotein IgG (s-IgG) response, while the ratio of positive spike glycoprotein IgM (s-IgM) reached 63%. Furthermore, moderate to potent neutralization activities were also observed in 62% of patients, correlating significantly with s-IgG response. This study strongly supports the long-term presence of antibodies in recovered patients against SARS-CoV-2, although all serum samples were collected from individuals with mild or moderate symptoms. Frontiers Media S.A. 2021-05-28 /pmc/articles/PMC8193946/ /pubmed/34122416 http://dx.doi.org/10.3389/fimmu.2021.659041 Text en Copyright © 2021 Tian, Liu, Jiang, Zhang, Liu and Li https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Tian, Xiaodong Liu, Ling Jiang, Wenguo Zhang, He Liu, Wenjun Li, Jing Potent and Persistent Antibody Response in COVID-19 Recovered Patients |
title | Potent and Persistent Antibody Response in COVID-19 Recovered Patients |
title_full | Potent and Persistent Antibody Response in COVID-19 Recovered Patients |
title_fullStr | Potent and Persistent Antibody Response in COVID-19 Recovered Patients |
title_full_unstemmed | Potent and Persistent Antibody Response in COVID-19 Recovered Patients |
title_short | Potent and Persistent Antibody Response in COVID-19 Recovered Patients |
title_sort | potent and persistent antibody response in covid-19 recovered patients |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8193946/ https://www.ncbi.nlm.nih.gov/pubmed/34122416 http://dx.doi.org/10.3389/fimmu.2021.659041 |
work_keys_str_mv | AT tianxiaodong potentandpersistentantibodyresponseincovid19recoveredpatients AT liuling potentandpersistentantibodyresponseincovid19recoveredpatients AT jiangwenguo potentandpersistentantibodyresponseincovid19recoveredpatients AT zhanghe potentandpersistentantibodyresponseincovid19recoveredpatients AT liuwenjun potentandpersistentantibodyresponseincovid19recoveredpatients AT lijing potentandpersistentantibodyresponseincovid19recoveredpatients |